By Rob Curran
Lantheus Holdings said an imaging agent designed to identify markers of Alzheimer's disease showed promise in two clinical trials.
The Bedford, Mass., maker of pharmaceuticals with radiological applications said its MK-6240 product candidate met primary end-points in clinical trials assessing its sensitivity and specificity. The company will use the data to support a New Drug Application to the Food and Drug Administration for the imaging agent in the third quarter.
The MK-6240 compound, used in Positron Emission Tomography, targets tau protein aggregation, associated with neurological diseases, including Alzheimer's disease.
"As a clinician, the ability to visualize tau pathology represents the opportunity for a seismic shift in how we diagnose and manage Alzheimer's disease," said Lantheus' medical director, Luca Passamonti.
Write to Rob Curran at rob.curran@wsj.com
(END) Dow Jones Newswires
April 30, 2025 09:02 ET (13:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。